{
  "pmid": "41445850",
  "title": "[",
  "abstract": "Immune checkpoint inhibitor treatment in non-small cell lung cancer (NSCLC) expands to early stages of disease. The neoadjuvant setting allows to investigate the mechanism-of-action of immune therapy using molecular imaging and tissue analysis. We investigated the safety and feasibility of programed cell death ligand-1 (PD-L1) PET-imaging with  This Phase I-II study (NCT03514719) enrolled 20 patients with Stage Ia-IIIa NSCLC who received two cycles of avelumab (10â€…mg/kg Q2W) prior to surgery. In the imaging optimization part, [ [ [",
  "disease": "lung cancer"
}